JAKARTA, April 30 (Reuters) - Indonesia's drug regulator on
Friday approved a COVID-19 vaccine produced by China's
Sinopharm, which is due to be used in a private vaccination
scheme under which companies can buy government-procured
vaccines to inoculate their staff.
No detailed efficacy data of Sinopharm's vaccine has been
publicly released, but its developer, Beijing Biological
Products Institute, a unit of Sinopharm subsidiary
China National Biotec Group (CNBG), said the vaccine was 79.34%
effective in preventing people from developing the disease,
based on interim data.
(Reporting by Agustinus Beo Da Costa and Stanley Widianto;
Editing by Ed Davies)